Rhythm is a biotechnology company developing peptide therapeutics that address unmet needs in metabolic diseases. Rhythm is developing the ghrelin peptide agonist, RM-131, for the treatment of diabetic gastroparesis and other GI functional disorders, and the MC4R peptide agonist, RM-493, for obesity and diabetes. Rhythm investors include MPM Capital, New Enterprise Associates, Third Rock Ventures, and Ipsen. The company is based in Boston, Massachusetts.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/13/12 | $25,000,000 | Series B |
Ipsen Third Rock Ventures | undisclosed |
| 11/27/12 | $8,000,000 | Series B |
Ipsen Pfizer Venture Investments Third Rock Ventures | undisclosed |
| 08/13/15 | $40,000,000 | Series A |
Deerfield Management Company, L.P. Ipsen MPM Capital OrbiMed Advisors Pfizer Venture Investments Third Rock Ventures Wellington Management Company | undisclosed |
| 02/17/17 | $41,000,000 | Mezzanine |
Deerfield Management Company, L.P. Ipsen MPM Capital OrbiMed Advisors Pfizer Strategic Investments Group Third Rock Ventures | undisclosed |
